SB 65: Substance abuse services; authorizing the possession, acquisition, distribution and administration of emergency opioid antagonists and adulterant test strips by any person. Effective date. Emergency. - Oklahoma

Floor (House) → Floor (Senate) · 5 edits

MODERATE

The bill was rewritten to shift its focus from providing emergency opioid treatment and immunity to regulating the destruction of seized or expired drugs. It now mandates that specific law enforcement agencies and medical examiners destroy controlled substances according to federal rules, with new thresholds for when police can destroy drugs on-site versus sending them to a central lab.

Scope change

The bill's scope changed from a public health measure allowing anyone to possess and administer opioid reversal drugs to a regulatory measure governing the disposal of seized or unwanted controlled dangerous substances by law enforcement and medical officials.

SCOPE

The primary subject matter changed from authorizing the possession and administration of emergency opioid antagonists to authorizing and regulating the destruction of controlled dangerous substances.

REQUIREMENT

New requirements were added for law enforcement agencies to destroy seized drugs on-site if the amount exceeds ten pounds, including specific steps like photographing the drugs and retaining samples for evidence.

The Office of the Chief Medical Examiner is now authorized to perform on-site incineration of controlled substances obtained during official duties.

DEFINITION

Definitions for 'adulterant test strips' and 'emergency opioid antagonist' were removed, while new procedures for submitting expired or unwanted drugs to the Oklahoma State Bureau of Investigation were added.

ELIGIBILITY

Provisions granting broad criminal and civil immunity to individuals who possessed or administered emergency opioid antagonists were removed.

SB65 (3-25-26) (WEAVER) FS FA1.PDF → Floor (House) · 5 edits

MODERATE

The House version of SB 65 expands the bill's scope by adding 'adulterant test strips' (such as fentanyl and xylazine detection tools) to the list of items that can be legally possessed, acquired, distributed, and administered. This change broadens the emergency response capabilities for opioid overdoses to include testing for common drug contaminants. The definitions for both the test strips and the emergency opioid antagonist were updated to reflect these new items, and the immunities from criminal and civil liability now cover the use of these test strips as well.

Scope change

The bill's scope was expanded to include the distribution and administration of adulterant test strips in addition to emergency opioid antagonists.

SCOPE

Added 'adulterant test strips' to the list of items that can be possessed, acquired, distributed, and administered.

DEFINITION

Updated the definition of 'Adulterant test strips' to include devices for detecting fentanyl, xylazine, or other substances used to adulterate controlled substances.

Updated the definition of 'Emergency opioid antagonist' to clarify it includes naloxone approved by the FDA.

REQUIREMENT

Expanded the list of authorized activities to include possessing, acquiring, distributing, and administering adulterant test strips.

ENFORCEMENT

Extended criminal and civil immunities to cover the distribution, availability, and administration of adulterant test strips.

House Committee Substitute for Senate Bill → SB65 (3-25-26) (WEAVER) FS FA1.PDF · 4 edits

MODERATE

The bill was reclassified from a 'Committee Substitute' to a 'Floor Substitute,' indicating it has moved to the final legislative stage for approval. The most significant substantive change is the removal of 'adulterant test strips' (devices for detecting fentanyl/xylazine) from the list of authorized items, limiting the law strictly to the distribution and administration of emergency opioid antagonists like naloxone. Additionally, the bill's page reference number was updated from 17481 to 3815.

Scope change

The scope of authorized items was narrowed by removing the authorization for test strips, focusing the law solely on opioid reversal drugs.

DEFINITION

The definition of authorized items was changed to remove 'adulterant test strips,' leaving only 'emergency opioid antagonists' (e.g., naloxone).

ELIGIBILITY

The list of permitted actions for any person was updated to remove references to possessing, acquiring, distributing, or administering test strips.

ENFORCEMENT

The immunity clause was updated to remove protections related to the handling of test strips, though protections for opioid antagonists remain.

TECHNICAL

The bill title was changed from 'Committee Substitute' to 'Floor Substitute,' and the internal page reference number was updated from 17481 to 3815.

Proposed Policy Committee Substitute 1 → House Committee Substitute for Senate Bill · 3 edits

MINOR

The bill was completely rewritten and renumbered from a Proposed Policy Committee Substitute to a House Committee Substitute. While the core text regarding opioid antagonist distribution remains largely similar, the document now reflects the House's version with updated committee numbers, revised section identifiers, and a new effective date of April 16, 2026.

Scope change

The bill's substantive scope regarding who can distribute emergency opioids appears unchanged, but the document has been formally transitioned from a policy proposal to a House committee substitute, indicating it is now ready for further legislative processing.

TECHNICAL

The entire document was replaced with a new version that updates the bill title from 'Proposed Policy Committee Substitute' to 'House Committee Substitute' and changes the bill number in the footer from 17275 to 17481.

Minor formatting and line number adjustments were made throughout the text to align with the new House version.

TIMELINE

The effective date or amendment date in the footer was updated from April 2, 2026, to April 16, 2026.

Enrolled (final version) → Proposed Policy Committee Substitute 1 · 3 edits

MINOR

The bill was amended to expand its scope by adding 'adulterant test strips' (devices to detect fentanyl and xylazine) to the list of items that individuals can legally possess, acquire, distribute, and administer. This change broadens the emergency response toolkit available to the public beyond just opioid reversal drugs.

Scope change

The bill's scope was expanded to include the legal distribution and possession of fentanyl/xylazine test strips in addition to emergency opioid antagonists.

DEFINITION

Added a new definition for 'adulterant test strips' to clarify that devices detecting fentanyl or xylazine are covered by the bill.

ELIGIBILITY

Expanded the list of authorized items to include both emergency opioid antagonists and adulterant test strips for possession, acquisition, distribution, and administration.

ENFORCEMENT

Updated criminal and civil immunity provisions to explicitly cover the possession and distribution of the newly added test strips.

Engrossed → Enrolled (final version) · 2 edits · May 13, 2026

MINOR

The bill transitioned from an 'Engrossed' draft to its final 'Enrolled' version, incorporating standard legislative formatting required for Governor approval. The substantive policy content regarding opioid antagonist laws remained unchanged, though the final version added a specific civil liability exception for 'gross negligence or willful or wanton wrongs' that was not explicitly detailed in the provided Engrossed text.

Scope change

No change in the bill's scope or applicability; the text remains substantively identical.

TECHNICAL

The document was updated from an Engrossed draft to an Enrolled final version, adding standard signatures and dates for the Senate, House, Governor, and Secretary of State.

ENFORCEMENT

The final version clarified civil liability protections by explicitly stating that immunity does not apply to acts or omissions constituting gross negligence or willful or wanton wrongs.

Introduced → Engrossed · 5 edits · Mar 30, 2026

MODERATE

This bill completely replaced the original text of SB 65, shifting the focus from controlled dangerous substance destruction protocols to a new law allowing any person to possess, acquire, distribute, and administer emergency opioid antagonists like naloxone. The new version grants broad immunity from criminal and civil liability to individuals acting in good faith to prevent opioid overdoses.

Scope change

The bill's scope changed from regulating how specific facilities and agencies must destroy unused drugs to authorizing any individual or entity to provide emergency overdose reversal medication.

ELIGIBILITY

Expanded eligibility to allow any person (not just registered facilities) to possess, acquire, distribute, and administer emergency opioid antagonists.

DEFINITION

Added a new definition for 'emergency opioid antagonist' covering drugs like naloxone approved by the FDA.

ENFORCEMENT

Granted immunity from criminal prosecution and civil liability for individuals acting in good faith to administer these medications.

REQUIREMENT

Removed all previous requirements regarding the submission, incineration, and record-keeping of destroyed controlled dangerous substances.

TIMELINE

Set the effective date of the new law to July 1, 2026.

Substance abuse services; authorizing the possession, acquisition, distribution and administration of emergency opioid antagonists and adulterant test strips by any person. Effective date. Emergency.

What changed between versions

How they voted

Actions timeline

Sponsors